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Despite the large implications of Major Depressive Disorder (MDD) on disease burden 
worldwide, current treatment options are suboptimal and a third of patients suffering from this 
disease do not respond to treatment. Therefore, an unmet need exists for the development of 
new treatment options and methods to aid appropriate treatment selection in individual patients. 
Selection of suitable biomarkers and reliable quantification methods are essential steps in this 
process. In recent research on MDD, more interest has arisen for the serotonin 1B (5-HT1B) 
receptor and for ketamine as a new antidepressant treatment option. This thesis focuses on the 
involvement of the 5-HT1B receptor and the related protein p11 in the pathophysiology of MDD 
and the antidepressant mechanism of action of ketamine. For quantification of 5-HT1B receptor 
densities, the nuclear imaging techniques Autoradiography (ARG) and Positron Emission 
Tomography (PET) were used. This work includes the development and application of an 
improved method for quantification of 5-HT1B receptor binding using PET. Quantification of 
p11 levels was performed in specific cell populations using Flow Cytometry. 
In study I, 5-HT1B receptor binding densities and cortical distribution were examined using 
ARG in anterior cingulate cortex tissue of subjects with MDD, schizophrenia, bipolar disorder 
and healthy controls. Binding of the radioligand [3H]AZ10419369 in tissue of in total 52 
subjects showed no significant differences between the subject groups. A distribution pattern 
with higher 5-HT1B receptor binding in supragranular layer compared to the infragranular layer 
was found, which correlated with glutamatergic N-methyl-D-aspartate receptor distribution. 
Female subjects had lower 5-HT1B receptor densities than male subjects, which was mostly 
profound in the MDD group. 
In study II, an improved method was developed for delineation of Volumes of Interest (VOIs) 
for PET data with the radioligand [11C]AZ10419369. Based on a 3D [3H]AZ10419369 ARG 
model in post mortem brainstem tissue and literature findings, appropriate VOIs for 
quantification in PET were selected. Two previously developed semi-automatic VOI 
delineation methods, based on template or individual data, were evaluated on test-retest data of 
8 healthy subjects and showed improved reliability compared to a conventional manual VOI. 
The VOIs created with PET template data of 52 healthy subjects can be automatically applied 
to future PET studies measuring 5-HT1B receptor binding in the brainstem.  
Furthermore, in a randomized placebo-controlled study the effect of ketamine on cerebral 
[11C]AZ10419369 PET binding (study III) and peripheral p11 protein levels measured with 
Flow Cytometry (study IV) were examined in patients with Selective Serotonin Reuptake 
Inhibitor (SSRI) resistant MDD. An increase in 5-HT1B binding in the hippocampus and a 
decrease in p11 levels in both cytotoxic T cells and T-helper cells populations were seen in the 
ketamine group (n=20), although both did not differ from changes seen in the placebo group 
(n=10). Changes in Montgomery-Åsberg Depression Rating Scale (MADRS) score after 
ketamine treatment correlated significantly with baseline 5-HT1B receptor binding in the ventral 
striatum and baseline p11 levels in cytotoxic T cells. Future studies should be conducted on the 
role of 5-HT1B receptors and p11 in the antidepressant mechanism of action of ketamine and 
should clarify if these proteins could be used as biomarkers to predict ketamine treatment 
response in subjects with SSRI-resistant MDD. 
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1.1 RATIONALE FOR THE THESIS 
Major depressive disorder (MDD) is the most common psychiatric disorder and a leading cause 
of disability worldwide that affects around 4.4% of the global population1. Despite the 
availability of various antidepressant treatment options, treatment success in MDD is limited2. 
About 30% of MDD patients need to try out multiple treatments before getting into remission 
and even more than 30% of MDD patients do not achieve remission at all, i.e. these patients 
are considered to have treatment-resistant depression3,4. Most MDD patients who do get into 
remission experience a relapse within 1-2 years4. Therefore, there is a large unmet need for 
improved treatment options, as well as improved methods to select effective treatments for 
individual patients. Relatively few new antidepressant drugs have been discovered in recent 
years5, which is likely caused by the insufficient understanding of the pathophysiology of 
MDD. The identification of reliable biomarkers is an important step in the process of improving 
knowledge on pathophysiology and the mechanism of antidepressants. 
Currently, the pharmacological treatment of MDD is primarily based on targeting the 
monoaminergic system. A common target for antidepressants is the serotonin transporter (5-
HTT), e.g. Selective Serotonin Reuptake Inhibitors (SSRIs). Because of a large proportion of 
treatment-resistant MDD subjects, drug development should probably be focused on a different 
target. The serotonin 1B (5-HT1B) receptor and its interaction with the protein p11 have recently 
received more interest as a possible target for pharmacological treatment of psychiatric 
disorders and seem interesting candidates as biomarkers for MDD.  
An important breakthrough in antidepressant drug development has been the coincidental 
finding of the antidepressant side effect of the analgesic drug ketamine6,7. However, its clinical 
implementation is limited by numerous other short-term and long-term side effects8. For the 
development of more suitable treatment options, it is highly desired to unravel the  
antidepressant mechanism of action of ketamine. Moreover, clinical decision making for this 
treatment option could be optimized when a biomarker for prediction of treatment outcomes 
becomes available.  
Neuropsychiatric research is challenging due to the complexity and low accessibility of the 
brain. Nuclear imaging techniques, such as Autoradiography (ARG) and Positron Emission 
Tomography (PET), are useful to retrieve biological insights of the brain in vitro and in vivo, 
respectively. Both ARG and PET enable accurate determination of protein levels in the brain. 
Relatively low resolution and high costs are limitations of PET, but this can partly be overcome 
by improved quantification methods which increase the reliability of outcomes and reduce the 
number of study subjects needed in future studies. ARG complements PET with its high 
resolution and possibility to examine receptor distribution in a controlled lab environment. 
While PET and ARG are excellent technique to study processes directly in the brain, a 
biomarker accessible in peripheral blood would be preferred for both patient comfort and 
implementation in clinical practice. Flow Cytometry can be used to quantify potential 
biomarkers in specific cell types, e.g. peripheral blood mononuclear cells. 
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The general aim of this thesis was to study the 5-HT1B receptor and p11 protein in MDD and 
treatment with ketamine. This was achieved by using in vivo PET and in vitro ARG and Flow 
Cytometry. Moreover, ARG was used to complement PET in the development of an improved 
quantification method. 
 
1.2 MAJOR DEPRESSIVE DISORDER 
MDD is characterized by depressed mood, anhedonia, fatigue, impaired attention control and 
disturbances in weight, sleep and movement9. The exact mechanisms underlying the disease 
process and current treatment options are still to a large extent unclear. Several systems and 
processes are suggested to be involved in the pathophysiology of MDD, among others: the 
hypothalamic-pituitary-adrenal axis, which regulates stress response; the immune system; 
neuroplasticity, i.e. the ability to grow and reorganize neuronal cells; and the monoaminergic 
neurotransmitter system in the central nervous system (CNS)10,11. Currently, guidelines in 
clinical practice suggest treatment for MDD with psychotherapy or pharmaceutical treatment 
interacting with the monoaminergic system, especially noradrenalin, serotonin (5-
hydroxytryptamine, 5-HT) and dopamine12.  
An association between MDD and the monoaminergic system was suggested after the 
discovery of the relation between the antidepressant side effect of the anti-hypertensive drug 
reserpine and monoamine depletion13. The role of serotonin in MDD was further supported by 
antidepressive agents that increased available serotonin concentrations14,15 and the effect of 
tryptophan (a serotonin precursor) depletion on relapse in MDD patients16. Studies in which 
levels of serotonin metabolites in plasma and post mortem tissue of patients with MDD were 
measured, did not provide definitive findings in relation to MDD10. Serotonergic 
neurotransmitter function in MDD is therefore thought to be impaired by malfunctioning of 
receptors and downstream mechanisms11. 
 
1.3 THE SEROTONIN SYSTEM 
1.3.1 Overview of the serotonin system 
Serotonin is a neurotransmitter involved in the vast majority of behavioral processes, although 
most serotonin receptors are found outside the CNS, e.g. in blood vessels and the 
gastrointestinal tract17. In the CNS, serotonin neurons originate in brainstem nuclei (Figure 1), 
where they are mostly situated in three separate regions close to the midline, i.e. the raphe 
nuclei: the caudally located raphe nuclei and the two rostrally located median and dorsal raphe 
nuclei. The two largest caudally located raphe nuclei are the raphe magnus and the raphe 
obscurus, which project towards the spinal cord. The median and dorsal nuclei both project to 
most subcortical and cortical regions; the striatum and hippocampus are nearly exclusively 
innervated by the dorsal and median raphe nuclei, respectively18. 
Serotonin receptors can be divided into 7 subgroups, based on their pharmacological profile, 
which can be subcategorized resulting in 14 currently known types of serotonin receptors19. 
These receptors are G-protein coupled receptors, except for the ligand-gated ion channel 5-HT3 
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receptor19. Previous studies in MDD subjects showed alterations in 5-HTT20, 5-HT1A receptor21 
and 5-HT2A receptor22 concentrations compared to control subjects. The 5-HT1B receptor 
currently receives increasing interest in research of the pathophysiology and treatment of 
MDD23,24. 
 
Figure 1: Serotonergic nuclei in the brainstem (raphe nuclei) and projections (red arrows) towards 
cortical (purple area) and subcortical regions. Figure created by using an image from Servier Medical Art 
(http://smart.servier.com/), licensed under CC BY 3.0 
 
1.3.2 Serotonin 1B receptor 
5-HT1B receptors are Gi/o-protein coupled and occur as both auto- and heteroreceptors, thereby 
inhibiting the release of respectively serotonin and other neurotransmitters25. In the central 
nervous system, the receptor is most abundant in the globus pallidus and substantia nigra26–28, 
whereas 5-HT1B mRNA is absent in these regions and instead found in high concentrations in 
the striatum and cortex26,27. This minimal co-localization is likely caused by the receptors’ 
predominant localization on axon terminals26.  
In animals, low 5-HT1B receptor activation has been linked to aggression29 and anxiety30. 
Moreover, human PET studies showed an association with anger31 and creative ability32.  
The link between the 5-HT1B receptor and MDD is well-studied, although findings are not 
always consistent. 5-HT1B receptor knock-out mice were shown to have less depressive 
symptoms compared to controls33. Moreover, increased 5-HT1B receptor levels were found 
throughout the brain in an animal model of MDD compared to controls34,35. However, reduced 
levels of 5-HT1B receptors in the hippocampus were associated with genetic and environmental 
vulnerability for MDD in rats36. Studies on 5-HT1B receptor mRNA expression in the raphe 
nuclei of rodents also seem conflicting, with increases in 5-HT1B receptor mRNA expression 
both being associated with MDD37 and with a protective function in MDD38,39. The discrepancy 
in these findings could be, among others, explained by the differences in MDD models used, 
analysis methods or heterogeneity within the studied regions.  
In humans, a polymorphism of the 5-HT1B receptor G861C gene has been associated with 
MDD40. In post mortem cortical tissue41, decreased 5-HT1B mRNA levels were found in suicide 
victims compared to tissue originating from healthy controls. In the anterior cingulate cortex 
of MDD subjects, mRNA levels were found to be lower compared to subjects with 
schizophrenia and bipolar disorder42. In vivo studies in MDD subjects showed lower 5-HT1B 
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receptor availability in hippocampus, anterior cingulate cortex43 and a volume containing the 
ventral striatum and pallidum44 compared to healthy control subjects.  
The 5-HT1B receptor has also been implicated in treatment of MDD. A reduction of 5-HT1B 
receptor availability was seen after treatment of MDD patients with cognitive behavior 
therapy45. Treatment with both 5-HT1B receptor agonists and antagonists has been associated 
with antidepressive effects46, possibly due to a difference in targeting either 5-HT1B auto- or 
hetero-receptors24. A commonly used antidepressant which acts as partial agonist towards the 
5-HT1B receptor47 is vortioxetine. Vortioxetine has been shown to bind to the 5-HT1B receptor 
in the non-human primate brain in vivo at clinically relevant doses48, although it is unclear to 
what extent this contributes to the antidepressant effect in humans. 
1.3.3 P11 
The protein P11 (S100-A10) plays a crucial role in 5-HT1B receptor functioning: the protein 
increases localization of the 5-HT1B receptor on the cell membrane and enhances its function49. 
P11 is a member of the calcium binding s-100 protein family50 and is also found to interact 
with 5-HT1D49, 5-HT451, metabotropic glutamate 552, CC chemokine 10 receptors53 and various 
ion channels54,55. P11 is mostly found in the lungs, intestines and kidneys56. In the brain, p11 
has a widespread distribution, although in lower concentrations56,57. Next to this, its presence 
is confirmed in peripheral blood mononuclear cells (PBMCs)58,59, with a 10-fold higher 
magnitude presence in monocytes59. 
Knockout of the p11 gene in mice was shown to exhibit a depressive-like phenotype, whereas 
the overexpression of p11 levels induced behavioral effects which are also seen after 
antidepressant treatment49. Moreover, administration of the antidepressant compounds 
imipramine or tranylcypromine, in combination with electroconvulsive shocks, increased p11 
mRNA in the cortex of mouse models of depression49. More recent studies have found that the 
induction of a depression-like behavior by p11 reduction is dependent on localization and cell 
type52,55,60. 
P11 mRNA expression in human MDD subjects was found to be decreased in frontocortical 
areas, the hippocampus, amygdala41 and anterior cingulate cortex (ACC)49. Likewise, 
reductions in p11 protein levels were found in the ACC49 and nucleus accumbens60 of MDD 
subjects compared to healthy control subjects.  
Interestingly, compared to findings in cerebral tissue, an opposite pattern seems to occur in 
peripheral blood: p11 mRNA expression and p11 protein levels in PBMCs were shown to be 
increased in MDD subjects compared to healthy subjects58. Likewise, protein p11 levels in 
PBMCs of Parkinson subjects with depression were increased in classically activated 
monocytes and cytotoxic T cells compared to healthy subjects61. Treatment with the SSRI 
citalopram showed an early reduction of p11 levels in monocytes and Natural Killer (NK) cells, 
which was predictive of improvements in depression symptoms59. Involvement of alterations 
in both innate and adaptive immune systems in MDD and treatment response has been well 
established62–64, although exact mechanisms remain elusive. The role of p11 in MDD should 





Ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, was first developed for its 
anesthetic and analgesic properties65. However, studies from the last two decades showed 
ketamine’s potential to act as an antidepressant with long-lasting effects in patients with 
treatment-resistant depression7,66–68. Unlike the slow onset of common antidepressants, 
ketamine has shown to induce a rapid antidepressant effect within hours7,68, while a single 
administration showed to be effective for a week68.  
Ketamine has historically been administered intravenously, but recently the American Food 
and Drug Administration approved the more patient-friendly S-ketamine nasal spray for 
treatment of treatment-resistant depression in adults, to be used in combination with an oral 
antidepressant. The clinical application of ketamine is still restricted due to its numerous side 
effects, including dissociative effects, loss of appetite, hallucinations and abuse liability8. 
Moreover, long term administration of ketamine has been suggested to induce cognitive deficits 
in humans and is associated with cell apoptosis in the prefrontal cortex of non-human 
primates69,70. Development of fast and effective MDD treatments, with less undesirable effects, 
may benefit from knowledge on the effects of ketamine. However, the antidepressant 
mechanism of action of ketamine remains largely unknown.  
Research on the antidepressant properties of ketamine has mostly been focused on the 
glutamate system2. The antidepressant action of ketamine was found to be dependent on the 
glutamate α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor71,72. 
Ketamine produces presynaptic glutamate release, and is suggested to exert its rapid effect by 
an increased activation of AMPA relative to NMDA receptors, which may activate 










Figure 2: Schematic representation of a suggested antidepressant mechanism of action of ketamine.     
1: Ketamine blocks NMDA-receptors, including those on GABAergic interneurons; 2. Inhibition of 
GABA release causes disinhibition of the glutamatergic neuron; 3. Glutamate is more excessively 
released; 4. Glutamate binds towards the AMPA-receptor on the postsynaptic neuron and is prevented 
from binding to NMDA-receptors by ketamine; 5. The increased glutamate AMPA vs NMDA 
throughput induces synaptic potentiation.71,72 Figure created by using images from Servier Medical Art 
(http://smart.servier.com/), licensed under CC BY 3.0 
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Ketamine also has strong effects on other mechanisms than NMDA inhibition: affinity has been 
shown towards opioid, muscarinic, nicotinic and serotonergic receptors73. A role for the 
serotonin system has been proposed in the antidepressant action of ketamine74. Serotonin 
depletion in rodent model of depression was shown to diminish the antidepressant effect of 
ketamine, which could be restored with a 5-HT1B receptor agonist75. In a non-human primate 
PET study, administration of ketamine increased the availability of 5-HT1B receptors in the 
ventral striatum, which was dependent on activation of the AMPA receptor76. Also, protein p11 
was demonstrated to play a role in the sustained antidepressant effect of ketamine in the 




1.5.1 Principles of Autoradiography 
The word autoradiography is derived from the Latin and Greek words auto (= self), radius 
(=ray) and graphein (to write); i.e. the studied object itself is the source of radiation. With this 
technique, an image is created from the pattern of decay emission on a film or emulsion. Due 
to the high sensitivity and high resolution of this technique, autoradiography can be used to 
localize and quantify radioligand binding78. ARG may provide an indication on whether a 
radioligand is suitable for in vivo PET, especially with regards to affinity, selectivity and non-
specific binding. 
In a typical in vitro ARG procedure, a sample (slice, tissue homogenate or cells from a cell 
culture) is incubated with radioligand solution, after which the sample is washed, dried and 
then placed in direct contact with either radiosensitive film, photostimulable phosphor plate or  
photographic emulsion. For the quantitative ARG experiments in this thesis, a 3H-labeled 
ligand and photostimulable phosphor films are used, together with calibrated radioactive 
samples. Upon decay of this radioisotope, a β-particle (electron) is emitted, which can excite 
electrons in the phosphor film. When the film is exposed to helium/neon laser light, the excited 
electrons go back to their ground state and a photon is released. These photons are recorded by 
a photomultiplier tube. The result is a record of localized light intensity, which is proportional 
to the amount of ionizing radiation. With the calibrated samples, this signal can be transformed 
into apparent binding densities.  
High resolution ARG, as also used in study I, is applicable when information regarding cellular 
location of the bound radioligand is required. The tissue sections are coated in photographic 
emulsion. This emulsion contains silver halides, which react to the beta particle decay, leaving 
silver grains. This results in a higher resolution radioligand signal, which can be studied by 
microscope. 
1.5.2 Ligand-receptor interaction 
A common application for ARG is to study the properties and interactions of a PET radioligand 
with its target. ARG enables the direct measurement of specific binding, the assessment of the 
affinity of the interaction and rate constants for the ligand-target interaction. This application 
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is complementary to in vivo PET and important for a direct comparison with in vivo brain 
images79. Using ARG, these properties can be studied in vitro on post mortem tissue in a 
controlled lab environment.   
Specificity towards the target can be directly measured using ARG by a competitive-binding 
assay: comparing radioligand binding with addition of excess cold ligand (not labeled with a 
radioactive isotope). When a cold ligand is used with known high specificity towards the same 
target, the resulting binding can give an indication of non-specific binding (Figure 3). Specific 
binding densities within the sample can then be calculated by subtracting the non-specific 
binding from total binding (i.e. radioligand binding without blocking with cold ligand). 
Administration of excess ligand in vivo could result in a pharmacological response and is 
therefore not desired. 
 
Figure 3: A) Concentration of ligand [L] plotted against concentration bound ligand to receptor [LR] 
for total binding (T), non-specific binding (NS) and specific binding (SB). B) Total binding of the 
radioligand [3H]PBR28 in the frontal lobe of a healthy subject. C) Consecutive slice of B, showing 
binding of [3H]PBR28 and blocking by excess PK11195, representing non-specific binding 
 
In vitro binding of ligand L to receptor R can be described schematically by equation 1.1, a 
derivation of a model proposed by Michaelis Menten for enzyme binding to a substrate. The 
rate constants of the forward and backward reaction of ligand binding to the receptor are kon 
and koff respectively. This equation shows that the rate at which binding of the ligand to the 
receptor occurs, is proportional to the concentration of ligand and receptor. Similarly, the 
dissociation rate is proportional to the concentration of bound receptor. In order to get a 
reproducible outcome measure, the concentration of bound receptor is measured after enough 
time has been allowed for the rate of association to be equal to the rate of dissociation, i.e. the 





As with enzyme kinetics, the receptor-ligand interaction reaches a plateau due to saturation of 
the receptor. For ARG quantification of receptor densities, radioligand concentrations approach 
saturation of the target (Bmax: total receptor density). This can be visualized by the saturation 
curve as shown in Figure 4 and is described by equation 1.2, a derivation of the Michaelis-
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Menten equation. When the concentration of free ligand equals Kd, the equilibrium dissociation 
constant, half of the maximum concentration of available receptors is bound. Kd is the ratio of 
the rate constants koff and kon. The reciprocal of Kd represents the affinity of the ligand towards 
the receptor. For radioligands, Kd typically describes concentrations in the nanomolar (nM) 
level. 
 
Figure 4: Saturation-binding curve: Concentration of ligand [L] plotted against concentration ligand 
specifically bound to receptor [LR]. The asymptote of the curve is Bmax, the maximum concentration of 
receptors in the sample. When [L] = Kd, the equilibrium dissociation constant, half of Bmax is bound.  





1.5.3 Resolution: ARG vs PET 
An advantage of ARG over PET is its relatively high spatial resolution. The resolution in ARG 
is < 0.1 mm80, while in PET, even when using the high-resolution research tomograph (HRRT) 
a resolution of 1.5 mm can be achieved81,82. This can partly be explained by the fact that 
radioisotopes suitable for ARG can have much lower energy (e.g 3H, energy: 6 keV) than 
radioisotopes suitable for PET (e.g. 11C, energy: 967 keV) 83. Lower radioactive energy beta-
particles travel a smaller distance from the source and therefore divert less from their original 
position. Moreover, detection of radiation at close proximity to the tissue also reduces the 
limiting effects of scatter on resolution. Radiation can be attenuated and scattered upon 
interaction with matter. The larger the distance between object and detector, the more the 
resolution will be negatively affected by scatter. Further factors determining resolution in PET 
are discussed in the next chapter. 
 
1.6 POSITRON EMISSION TOMOGRAPHY 
1.6.1 Application 
PET is a non-invasive imaging technique that can provide functional information of the brain 
in vivo. It has a high sensitivity and specificity, enabling visualization and quantification of 
biochemical and metabolic processes. PET can facilitate drug discovery in microdosing, 
occupancy and biomarker studies84. In microdosing studies, a drug candidate is labeled with a 
radioactive isotope. This enables the examination of the uptake and distribution of the drug 
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throughout the body and therefore also enables the assessment of penetration of the blood-brain 
barrier (BBB). In occupancy studies, radioligand binding is studied before and after 
administration of a drug. In this way, the receptor population occupied by the drug can be 
defined. This can be useful to investigate whether the target is engaged in the working 
mechanism of the drug85 or to guide drug dose selection86. In biomarker studies, target proteins 
can be studied in relation to pathophysiology, disease progression, monitoring treatment effect 
and studying the mechanism of a drug. The most common application in clinical practice for 
PET is the use of a biomarker for glucose metabolism in cancer: 18F-FDG 
(fluorodeoxyglucose)87, to measure localized increases of glucose utilization. In the CNS, PET 
radioligands are, among others, used to examine β-amyloid load, a biomarker used for 
diagnosis of Alzheimer’s disease88. Although several biomarkers have been proposed for 
psychiatric disorders, there is currently no consensus for their use in clinical practice. 
1.6.2 Radioligand 
The high specificity of PET is dependent on the use of specific ligands labeled with a 
radioactive isotope (a radionuclide). Common ligands for use in PET are radiolabeled with a 
short-lived nuclide, such as 11C (half-life = 20.3 min), which is also used for the radioligand 
applied in this thesis. Radionuclides with a longer half-life, such as 18F (half-life  = 110 min) 
are needed in case there is no cyclotron to produce the radionuclide and a radiochemistry 
facility at the study site. Radioligands should have high affinity and high selectivity for the 
target, while showing low non-specific binding. Furthermore, PET ligands suitable for CNS 
imaging are designed taking into account the pharmacokinetic properties shown in Table 184,89. 
Table 1: Criteria of PET ligands in relation to pharmacokinetics 
Pharmacokinetic parameter Key Criteria 
Absorption (through BBB) Allow passive diffusion through BBB, e.g. size: < 500 Da,  
< 80Å2, lipophilicity: partition coefficient (log P): +1 to +4 
Not a substrate for P-glycoproteins (efflux transporter) 
Limited penetration of metabolites through BBB 
Distribution Low (pharmacological) volume of distribution 
Low plasma protein binding 
Limited accumulation in peripheral tissue compartments 
Metabolism Limited peripheral metabolism 
No central metabolism 
Elimination Rate: enable observation of washout for kinetic analysis 
BBB: blood brain barrier 
The produced radioligand should enable administration of a low injected mass. In that case, the 
proportion of unlabeled ligand is low, which minimizes the competition with the binding of 
labeled ligand towards the target. Moreover, the labeled ligand concentration should be 
sufficient to be detected by the PET system. This is represented by a high molar activity: the 




During the PET examination, the radioligand is commonly administered through venous 
injection. The radioligand is then distributed throughout the body via the blood stream after 
which it can bind to the target of interest. Radionuclides used in PET are β+-emitters, i.e. they 
emit positrons upon decay. This positron will travel a short distance, called the positron 
range90, before it collides with an electron. The positron range is positively correlated to the 
energy of the radionuclide; for 11C, the positron range is about 1 mm90. The collision of a 
positron and an electron induces annihilation, which induces the emission of two γ-photons in 
approximately opposite directions (Figure 5). The fact that these photons do not travel exact 
opposite directions is called the photon non-collinearity effect91. The photons are detected by 
the PET system, which contains a ring of detectors around the study subject. When two photons 
are detected within a certain timeframe, it will be recorded as a coincidence event. Together, 
these two detected photons provide positional information on where the annihilation has taken 




Figure 5: Schematic representation of signal detection in the PET system. Right: A collision of a 
positron (blue) with an electron (orange) results in annihilation, after which two γ-photons are emitted 
towards approximately opposite directions. The γ-photons detected within a short time frame are 
recorded as a line of response (red line) between two detectors. It is assumed that somewhere along this 
line of response the annihilation took place. Part of the figure is created by adapting images from Servier 
Medical Art (http://smart.servier.com/), licensed under CC BY 3.0 
 
After collection of all the coincidence events during a PET examination, a 3D representation 
of the radioactivity distribution is reconstructed. Many photons are however also detected as 
coincidence events, while they actually originate from two different annihilations (‘random 
events’) or from scatter. The detection of these erroneous line of responses are to a large degree 
corrected for by the reconstruction process, which limits resolution loss and noise in the data. 
Other factors influencing the resolution include: the size and material of the used detectors92, 
the positron range (annihilation does not take place at the exact location where the radioligand 
decayed) and the photon non-collinearity effect. The resolution limitation in PET leads to areas 
with spill-over and spill-in of signal originating from nearby areas, called the partial volume 
effect (PVE)93. Resolution in PET systems is being improved by technological developments 
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in detection systems94 and the application of more advanced reconstruction methods82. The 
impact of photon non-collinearity and scatter on resolution is reduced in PET systems designed 
for brain imaging compared to whole body PET, by decreasing the diameter of the ring of 
detectors. 
1.6.4 Quantification 
Ligand binding can be quantified per voxel (3D pixel) or as average in all voxels in a volume 
of interest (VOI). In order to define regions of interest PET, PET is ideally complemented by 
a modality which can provide anatomical information. Commonly, Magnetic Resonance 
Imaging (MRI) is used for this purpose. MRI provides information on proton densities, e.g. 
cerebral gray and white matter can be differentiated on MR images due to differences in the 
concentration of H2O, which is rich in protons. The MR image is co-registered to the PET 
image to enable the measurement of radioactivity in a VOI. 
In this thesis, 3D dynamic PET data is acquired, i.e. a series of 3D PET images are acquired 
during multiple time frames. When plotting the radioactivity concentration of each time frame 
within each voxel or VOI, a time activity curve (TAC) is obtained. In contrast to ARG, there is 
no option to directly measure the concentration of specifically bound ligand to the receptor for 
quantification with PET. Instead, measured radioactivity is normalized to a reference factor as 
an estimate of specific binding. In clinical practice, the Standard Uptake Value (SUV) is used. 
To calculate the SUV, measured radioactivity concentration at a predefined time is normalized 
by the injected dose divided by the body weight of the study subject. However, the validity of 
this outcome measure is strongly affected by noise, image resolution and definition of the 
region of interest95. In biomedical research, more robust outcome measures are desired. For the 
PET studies in this thesis, binding potential is used as outcome measure, which is defined as 
the ratio of Bmax (total receptor density, see section 1.5.2) to Kd (radioligand equilibrium 
dissociation constant)96. This means that binding potential is both dependent on receptor 
densities and the affinity of the ligand for the receptor. It is generally assumed that affinity does 
not differ between study subjects or brain regions, hence differences in binding potential reflect 
differences in receptor concentrations97.  
For a comparison of the in vivo outcome measure binding potential with the in vitro outcome 
measure specific binding, equation 1.2 (regarding in vitro receptor ligand binding) can be 
redefined to in vivo terms, where concentration of bound receptor [LR] = B and concentration 
of free ligand [L] = F: 





During in vivo PET measurements, receptor binding does not approach saturation. Instead, only 
a tracer dose of the radioligand is used, often occupying <5% of available receptors96. This 
prevents the occurrence of a pharmacological response, which would influence the in vivo 
system and could affect the study subject. In this way, injected radioactivity can be kept to a 
minimum even with high molar activity and low injected mass. Tracer dose conditions are used 
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to derive a robust outcome measure, which can be explained as follows: for in vivo PET, the 
concentration of F will be much lower than Kd and equation 1.3 can be rearranged to: 










Therefore, at tracer dose conditions, binding potential can also be described as the 
concentration of bound ligand to concentration of free ligand. Then, the ratio of the 
concentration of bound ligand to free ligand is a constant. This is visualized in the plot 
displayed in Figure 6, similar to the saturation curve described for in vitro binding (Figure 4). 
When the concentration of bound and free radioligand are very low, the slope is linear: if the  
concentration of free ligand increases, the concentration of bound linear increases 
proportionally. Small differences in injected radioligand therefore do not affect binding 
potential. Note that even though only a small proportion of the receptors are occupied at tracer 
doses, binding potential represents binding of the total amount of receptors. 
 
 
Figure 6: Saturation-binding curve: the concentration of free radioligand (F) plotted against the 
concentration of bound radioligand to the receptor (B). The initial slope of the curve is linear. At tracer 




 (equation 1.4). 
 
In order to measure the binding potential in the VOI or voxel, a kinetic model is used. As 
mentioned earlier, instead of measuring specific binding directly, when using in vivo PET, 
measured radioactivity is normalized to a reference factor. This reference factor can for 
example be radioactivity concentration measured in arterial plasma, or as used in this thesis: 
radioactivity concentration in a reference region in the brain which contains negligible amounts 
of the target. The model should describe the TAC and the behavior of radioligand binding in 
the tissue region of interest and in the reference region. Commonly, compartmental models are 
used for this purpose. These compartments represent the different physical locations (e.g. brain 
tissue, blood) or states (e.g. bound, free) in which the radioligand transfers and contains a 
homogeneous tracer concentration. As the behavior of different radioligands can differ, they 
might also be better described with different number of compartments and rate constants 
between compartments98,99.  
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The basis for most compartmental models to describe radioligand binding in PET is the three 
tissue compartment model (Figure 7A). This model describes the transfer of radioligand 
concentration from plasma (CP) to free ligand in target tissue (CF) and vice versa, with rate 
constants K1 and k2 respectively; transfer of radioligand from CF to specifically bound ligand 
(CS) and vice versa, with rate constants k3 and k4 respectively; and transfer of radioligand from 
CF to non-specific binding (CNS) and vice versa, with rate constants k5 and k6 respectively. 
When the transfer between the compartment with non-specific binding and the one with free 
tracer is assumed to be sufficiently fast, both can be collapsed into one compartment containing 
non-displaceable binding (CND).  
 
Figure 7: A) Three tissue compartment model. Boxes represent compartments describing radioligand 
concentration in: plasma (CP), free ligand in target tissue (CF), specifically bound ligand (CS) and non-
specifically bound ligand (CNS).  
B) Simplified Reference Tissue Model, with compartments describing total radioligand concentration 
in target tissue (CT) and reference tissue (CR). 
 
 
TACs from the radioligand used in this thesis have been shown to be well described28 by the 
Simplified Reference Tissue Model (SRTM)100 (Figure 7B). Rate transfer between CNS and CF 
are considered sufficiently fast to collapse into one CND compartment. Furthermore, this model 
uses a brain tissue region as reference, assumed to contain no specific binding. The 
compartment for the reference region (CR) therefore only contains one compartment with CND. 
In the target tissue, the rate of transfer between CND and CS is considered to be sufficiently fast 
enabling the possibility of these two compartments to be collapsed into one total tissue 
concentration compartment (CT). The rate constants for transfer from and to CP and CT are K1 
and k2, respectively; for transfer from and to CP and CR the rate constants are K’1 and k’2, 
respectively. It is not possible to separately derive K1 and K’1, instead this is derived as the 
ratio R1 = '(
')(













which results in three parameters to be estimated: R1, k2 and the outcome measure non-
displaceable binding potential (BPND). BPND is defined as the ratio of specific concentration to  
 
14 






where CT represents total radioligand concentration in target tissue and CR the total 






where fND represents the free fraction of ligand in the non-displaceable compartment and Bavail 
is the concentration of receptors available for measurement in vivo (as opposed to Bmax in ARG, 
where all receptors are theoretically available for the radioligand to be bound). When assuming 
that fND does not differ between study subjects, just like is assumed for Kd, BPND represents an 
estimation of the densities of available receptors in the target region.  
1.6.5 Imaging the 5-HT1B receptor 
In PET imaging studies focusing on 5-HT1B receptor densities, currently two ligands are being 
used: [11C]P943101 and [11C]AZ10419369102. Both radioligands have shown good test-retest 
reliability103,104. Although no direct comparison has been made so far, [11C]AZ10419369 has 
shown to result in higher affinity105 and BPND in human subjects28,106, which could reflect a 
higher signal-to-noise ratio. Both [11C]AZ10419369107–109 and [11C]P943110,111 have been 
shown to be sensitive to pharmacologically induced changes of endogenous serotonin levels. 
[11C]AZ10419369 PET is selective for the 5-HT1B receptor with high binding in the 5-HT1B 
rich cortical regions28,102 and low binding in the cerebellum28,102, a region known to be nearly 
devoid of 5-HT1B receptors112,113. AZ10419369 acts a partial agonist for the 5-HT1B receptor105, 
i.e. although it fully binds to the receptor, it does not induce a full pharmacological effect.  
Although test-retest reliability of quantification with [11C]AZ10419369 has been shown to be 
good in cortical regions and acceptable in subcortical regions, high variability of 5-HT1B 
receptor density measures has been seen in the dorsal part of the midbrain104. The relatively 
low reliability for quantification in the brainstem is likely caused by the poor visibility of small 
brainstem nuclei on MRI, therefore requiring an alternative approach for delineation of a VOI. 
Previously, methods have been reported to improve 5-HTT density quantification in brainstem 
nuclei114,115. Whether these methods are applicable for 5-HT1B receptor density quantification 
is uncertain, as the 5-HT1B receptor has in vitro been shown to possess a different distribution 
pattern and receptor density113. For example, in the substantia nigra and the central gray area, 
high 5-HT1B receptor densities were found112,116, while in the dorsal raphe nuclei, 5-HTT 
receptors were more abundant113. This difference in localization is likely to be explained by 
their functional differences: while 5-HTT are only located on serotonergic neurons, 5-HT1B 
receptors can also function as heteroreceptors on other neuron types25. Therefore, 5-HTT 




2 RESEARCH AIMS 
The overall objective of this thesis was to study cerebral 5-HT1B receptor densities and 
peripheral p11 protein levels in MDD patients in relation to treatment with ketamine. The 
specific aims were to investigate: 
Study I: The in vitro ARG distribution of 5-HT1B receptor densities in the anterior cingulate 
cortex at high resolution and to investigate if 5-HT1B receptor densities in MDD subjects could 
be differentiated from those in subjects with schizophrenia, bipolar disorder and healthy 
subjects. 
Study II: The in vitro ARG distribution of 5-HT1B receptor densities in brainstem tissue from 
a healthy subject and to use this information to improve a quantification method of 5-HT1B 
receptor availabilities in the brainstem using PET. 
Study III: The effect of ketamine treatment in SSRI-resistant MDD subjects on 5-HT1B receptor 
availability using PET, in relation to treatment response. 
Study IV: The effect of ketamine treatment in SSRI-resistant MDD subjects on p11 levels in 
peripheral blood using Flow Cytometry. As in study III, this effect is studied in relation to 
treatment response to examine the possibility that peripheral p11 could serve as a biomarker of 






3 MATERIALS AND METHODS 
3.1 ETHICAL CONSIDERATIONS 
All studies were approved by the Ethics Committee of the Stockholm Region. Additionally, 
study II was also approved by the Semmelweis University Human Ethical Committee and study 
III was approved by the Radiation Safety Committee of the Karolinska University Hospital. 
Study I and II contain post mortem tissue from anonymous donors. For study II-IV, subjects 
gave their written and verbal consent before initiation of study procedures. For study III-IV, 
patients were carefully informed about the risks of withdrawing medications. Personal data was 
carefully stored at a secure network and acronyms were used during analysis. 
Study III was carried out double-blind and analysis of the PET data was also carried out blinded 
to treatment allocation. Furthermore, the analysis protocol of this study was pre-registered, 
including for example the VOIs to be analyzed. 
 
3.2 AUTORADIOGRAPHY (STUDY I-II) 
3.2.1 Post mortem brain tissue 
None of the donors had known history or symptoms of neurological or psychiatric disorders 
(except for those studied in study I) and none of the brains exhibited damages or abnormalities 
from examination at autopsy and during sectioning. 
Study I: Human post mortem brain tissue was obtained from the Stanley Foundation, Bethesda, 
USA, who collected brains with family permission. Tissue originated from the ACC from the 
Neuropathology Consortium brain collection117, of which the present project had access to the 
following subset: brain slices derived of 52 individuals between 25 and 68 years old, of which 
14 diagnosed with bipolar disorder, 12 with MDD, 13 with schizophrenia and 13 healthy 
control subjects (the original collection consisted of material of 15 subjects of each group). The 
key to medical relevant information (such as diagnosis and age) was provided after data was 
sent to the Stanley Foundation. 
Study II: Human brain tissue (Table 2) was obtained post mortem at clinical autopsy at the 
Department of Forensic and Insurance Medicine, Semmelweis Medical University (Budapest, 
Hungary); the National Institute of Forensic Medicine, Karolinska Institutet (Stockholm, 
Sweden) and at the Human Brain Tissue Bank (Budapest, Hungary). 
Table 2: Demographic and clinical specifications of donated brain tissue for study II 
Region Age (y) Sex PMI (h) Cause of death 
Hemisphere 54 M 22-23 Coronary heart disease 
Hemisphere (L) 59 F 11 Cardiac failure in septic state 
Hemisphere (L) 63 M 48 Myocardial infarction 
Brainstem (R) 68 M < 24 Right ventricle failure 
Brainstem  34 F < 24 Thrombotic occlusion of pulmonary arteries 




The radioligand [3H]AZ10419369102 (Figure 8) was used for the ARG experiments of study I 
and II. [3H]AZ10419369 has shown high specificity and affinity for a single binding site on 
human 5-HT1B receptors118, which makes this radioligand highly suitable for studying the 5-
HT1B ligand in detail. [3H]AZ10419369 was synthesized at Karolinska Institutet, department 
of Clinical Neuroscience (study I) and purchased from Novandi Chemistry AB (Södertälje, 
Sweden; study II). Molar activity was 21 Ci/mmol and 83 Ci/mmol, respectively. 
Radiochemical purity was >98%. Kodak NTB emulsion was purchased from VWR, Sweden. 
 
Figure 8: The serotonin 1B binding ligand AZ10419369, labeled with either 11C (R1) for use with the 
PET studies (study II & III) or with 3H (R2) for use with the ARG studies (study I & II) in this thesis 
 
3.2.3 Cryosectioning 
Fresh frozen post mortem tissue was sectioned on a cryomicrotome (Leica CM 1860 Leica, 
Nussloch, Germany) or heavy-duty cryomicrotome (Leica cryomacrocut CM3600), thaw 
mounted to poly-l-lysine-treated or gelatinized glass plates, dried at room temperature and 
stored according to the specifications in Table 3. 
Table 3: Specifications for cryostat procedure 
 Region Plane Slice thickness Storage temperature 
Study I ACC Axial 14 µm -70°C 
Study II Hemisphere Axial: 3-4 levels 100 µm -25 °C 
 Brainstem Sagittal & Axial 20µm -20 °C 
 
In study II, the sagittal brainstem slides were sectioned leaving 0.5 mm of tissue between 
each consecutive slide. Photographic images of the frozen tissue were digitally recorded 
before cutting of each section and at the end of the cryostat wheel crank course, as previously 
described119.  
3.2.4 [3H]AZ10419369 in vitro autoradiography 
Sections were incubated at room temperature for 60 minutes in 1.5 nM [3H]AZ10419369 in 
buffer containing Tris-HCl 50 mM, pH 7.4 incl. 4 mM MgCl, 4 mM CaCl2. In study II, 0.1% 
bovine serum albumin was added to the incubation buffer to decrease non-specific binding, e.g. 
to the tissue embedding material carboxymethyl cellulose, which was not used in study I. 
Adjacent sections were simultaneously incubated in the previously mentioned buffer with 
addition of 10 µM 5-HT. After washing and drying, sections were placed together with 
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autoradiographic micro-scale standards (American Radiolabeled Chemicals Inc.), and exposed 
to phosphor imaging plates (Fujifilm Plate BAS-TR2025, Fujifilm, Tokyo, Japan) for four 
days. Image radioactivity was detected using a Fujifilm BAS-5000 phosphor imager (Fujifilm, 
Tokyo, Japan), which resulted in scanned images with signal representing average 
photostimulated luminescence (PSL)/mm2. 
3.2.5 High resolution autoradiography (study I) 
High resolution microscopic emulsion ARG was performed in order to visualize the cellular 
distribution of the radioligand in the ACC. Slices were dipped into NTB emulsion at 42°C, air-
dried at room temperature and exposed in the dark at 4°C for 3-4 weeks. Slides were then 
developed with Dokumol developer, rinsed in water, fixed with Vario Fix in room temperature 
and washed with water. 
3.2.6 Nissl staining 
Nissl staining was performed to provide anatomical information and guide definition of 
Regions of Interest (ROIs). Slides were stained with cresyl violet (Histolab, Göteborg, 
Sweden), dehydrated consecutively in increasing concentrations of ethanol, immersed in 
Histolab Clear (xylene substitution, Histolab, Göteborg, Sweden), dried and mounted. 
3.2.7 Defining regions of interest 
Guided by Nissl-staining, gray matter ROIs were manually drawn using Multi Gauge 3.2 
phosphor imager software (Fujifilm, Tokyo, Japan). Using the processed micro-scale 
standards, mean PSL/mm2 of each ROI was transformed into radioactivity values and binding 
density (pmol/mg tissue wet weight). Specific binding was determined by subtracting the level 
of non-specific binding from the total binding. 
3.2.8 Volume rendering (study II) 
Image preprocessing was performed using Fiji/ImageJ120 version 1.50i. Photographic images 
taken during cryosectioning were used as a reference volume for the processed ARG and Nissl-
stained brainstem sections, to control for possible sectioning related deformations121. First the 
photographic images were aligned and stacked. Then the ARG binding slices were co-
registered section-to-section to the photographic volume, using the Nissl-stained slices as 
intermedial modality. Subsequently, an ARG specific binding stack was generated by 
subtracting the information of the non-specific binding slices from the total binding slices, after 
which the stack was mirrored to represent ARG binding in a complete brainstem.  
The ARG brainstem volume was transformed into the standard reference space of the Montréal 
Neurological Institute (MNI122). This was performed by first using an affine transformation 
towards a substantia nigra weighted brainstem and subsequently applying a non-linear 
registration. 
ARG images of [3H]AZ10419369 on axial slices were used to confirm binding localization 
visually in the axial plane. 
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3.3 POSITRON EMISSION TOMOGRAPHY (STUDY II-III) 
3.3.1 Study subjects 
Health of the subjects (study III: excl. their MDD) was confirmed by medical history and 
physical examination, including routine blood tests and MRI of the brain. 
Study II: This study included data from 60 healthy subjects, of which 52 were pooled and used 
to create a database. This includes data from 33 subjects of which results were previously 
published in PET-studies107,123–125. Furthermore, 8 subjects were part of a test-retest study104 
and were in this study used for testing purposes in this study. The database consisted of 32 male 
and 20 female subjects, 38.2 ± 17.9 years of age (mean ± SD); the testing subjects were all 
male and 23.0 ± 2.3 years of age.  
Study III: Patients were recruited through internet-based advertisement. Patients had an 
ongoing MDD episode according to Mini International Neuropsychiatric Interview126, with 
MADRS126 score of ≥20 and were treated for at least four weeks with an SSRI in adequate 
doses without treatment response. Patients were randomly allocated to either active treatment 
with ketamine (n=20; 8 females; age = 39.2 ± 11.6 years; baseline MADRS = 26.3 ± 6.6) or 
placebo treatment (n=10; 6 females; age = 37.1 ± 11.2; baseline MADRS = 30.8 ± 4.9). 
3.3.2 Treatment protocol (study III) 
An antidepressant washout period of at least 5 drug half-lives was carried out prior to initiation 
of the examinations. At baseline, MADRS scores were assessed, venous blood samples were 
collected and the first PET examination was carried out. Within 2 days subjects were 
administered study treatment (double-blind, either active treatment with 0.5 mg/kg racemic 
ketamine diluted in 100 mL isotonic NaCl solution or placebo treatment with 100 mL isotonic 
NaCl solution) as one intravenous infusion for 40 minutes. A second MADRS assessment, 
blood sample withdrawal and PET examination were carried out 1-2 days after treatment. 
Subsequently, subjects in both groups were treated with open-label ketamine in 2-4 occasions 
within 2 weeks, after which a final MADRS assessment was performed. 
As the MDD symptoms insomnia and loss of appetite are also reported side effect of ketamine8, 
calculations on changes in symptom severity were based on an adjusted MADRS in which 
these two factors were left out, resulting in an 8-item MADRS, as preregistered at 
Aspredicted.org (#17602).  
3.3.3 PET examinations 
[11C]AZ10419369 (Figure 8) was synthesized as previously described102. All PET 
examinations were performed using the HRRT (Siemens Molecular Imaging, Knoxville, 
USA). A bolus injection of [11C]AZ10419369 was administered after which the intravenous 
line was flushed with saline. To minimize head motion during the PET examination, an 
individually made plaster helmet was used. Emission data was acquired in list mode for 63 to 
95 min and dynamic images were reconstructed in a series of 32-38 time frames using 3D 
ordinary Poisson ordered subset expectation maximization, including modeling of the system’s 
point spread function. This reconstruction protocol has previously been shown to provide a 
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resolution of approximately 1.5 mm full width half maximum in the center of the field of view 
and 2.4 mm at 10 cm away from the center82. 
3.3.4 MRI examinations and analysis 
T1-weighted MR images were acquired on a 3T GE MR750 scanner (GE Medical Systems, 
Milwaukee, WI; study II & III) and a 1.5T GE Signa (GE Medical Systems, Milwaukee, WI) 
or 1.5T Magnetom Avanto (Siemens Medical Solutions, PA, USA; study II: two subjects in 
database). These MR images were co-registered with PET images and segmented into gray 
matter, white matter and cerebrospinal fluid using SPM12. Furthermore, inverted co-
registration parameters were obtained to transform VOIs from MR to PET space. VOIs outside 
the brainstem were defined using Freesurfer (5.0.0, http://surfer.nmr.mgh.harvard.edu/). 
3.3.5 PET image analysis 
Images were corrected for head motion with a post-reconstruction frame-to-frame correction 
realignment algorithm as previously described127, and in the case of excessive head motion, 
with an additional motion correction algorithm based on the simplex method128. All PET data 
underwent minor motion correction using a frame-by-frame correction algorithm from SPM12.  
For VOIs outside the brainstem, BPND was calculated using SRTM, with the cerebellum as 
reference region. For analysis of VOIs in brainstem, a wavelet-aided parametric imaging 
(WAPI) algorithm129 was used to create parametric BPND images. This approach uses a 
reiterative wavelet-based denoising method and the non-invasive Logan plot fitted by 
multilinear regression to calculate BPND in each voxel. This method overcomes the VOI-size 
limitation of VOI-based compartment modeling and can therefore be used to quantify small 
brainstem regions. For study III, regional BPND values in the dorsal brainstem were calculated 
using the [11C]AZ10419369 template dorsal brainstem VOI (see below). 
3.3.6 Development of the 5-HT1B PET template (Study II) 
A [11C]AZ10419369 template was created with T1-weighted MR images and parametric PET 
images of 52 subjects. T1-weighted MR images were normalized to the standard reference 
MNI-space122 using FSL130 (FSL 5.0, Oxford). After skull-stripping with BET131, linear 
transformation was performed with FLIRT132, followed by non-linear transformation with 
FNIRT133. The obtained non-linear transformation parameters were then used to normalize the 
co-registered parametric images into MNI-space. Subsequently, average images were created 
from both modalities.  
3.3.7 Definition of brainstem VOIs (Study II)    
Three VOIs were selected based on 2D ARG data reported in the literature112,116,134 and visual 
inspection of the 3D [3H]AZ10419369 ARG model: 1) a dorsal brainstem VOI, including 
dorsal and median raphe nuclei, periaqueductal gray, superior and inferior colliculi; 2) a 
substantia nigra VOI; and 3) a caudal brainstem VOI encompassing the 5-HT1B receptors in 
the caudal part of the pons and medulla oblongata.  
Estimated localization of VOIs was guided by landmarks reported in literature18,135. The final 
VOIs were generated and applied on test-retest data of 8 subjects by two previously reported 
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methods based on: 1) individual PET data136 and 2) template PET data137 of [11C]AZ10419369 
binding, as shown in Figure 9. Both methods were compared to results using the conventional 
method, i.e. a manually drawn VOI encompassing the dorsal and median raphe nuclei104. 
 
Figure 9: Template-based method. 1: PET images were co-registered to MRI data, averaged and 
normalized to MNI-space. Oversized VOIs were drawn on BPND maps. 2: VOIs were eroded based on 
volumes from literature findings138–141 and highest radioligand binding. VOIs were then transformed to 





3.4 FLOW CYTOMETRY (STUDY IV) 
Flow Cytometry allows quantification of proteins expressed by individual cell populations, 
even in the case of intracellular proteins (as is the case for p11). The sample is mixed with 
antibodies conjugated to fluorescent dyes (fluorophores) and is directed to flow in a fluid 
stream through a beam of light. Emission spectra of the fluorophores are detected by the flow 
cytometer, which is calibrated to enable translation into a quantitative outcome measures (here: 
median fluorescence intensities (MFI)). The MFI provides a quantitative outcome measure for 
antigen expression per cell142. 
3.4.1 Subjects 
Study IV was a secondary study of study III. All subjects in this study participated in study III 
and underwent examinations as described above. One subject from the ketamine group was 
excluded from the current study, as the MFIs of p11 at baseline were considered as outliers in 
all cell populations, resulting in 29 study participants.  
3.4.2 PBMC Preparation 
At baseline, within the same day as assessment of MADRS scores, venous blood samples were 
collected into tubes containing ethylenediaminetetraacetic acid. Using a standard procedure, 
samples were processed within 2 hours of collection. PBMCs were extracted by low-density 
gradient centrifugation using Lymphoprep (Axis-Shield). Isolated PBMCs were stored at 
−80°C in 90% fetal bovine serum/10% dimethyl sulfoxide until assay.  
3.4.3 Sample preparation 
PBMCs were processed as follows: frozen PBMC aliquots were thawed quickly and 
subsequently washed with PBS. Near-IR dead cell marker (Invitrogen, #L10119) was used to 
perform viability staining. After washing, cells were fixed and permeabilized with 
Cytofix/Cytoperm solution (BD, #554714) for 20 min, after which they were stained with 
monoclonal mouse anti-annexin II light chain (i.e. p11) antibody (5 μg/mL, clone 148; BD 
Transduction Laboratories™, #610071) or isotype control mouse IgG1 antibody (5 μg/mL, 
clone MOPC-21; BioLegend, #400124) for 45min at RT. Secondary staining was performed 
with APC-conjugated goat anti-mouse antibody (2 μg/mL; BioLegend, # 405308) for 30 min 
at RT. After washing and incubation in blocking buffer (1% mouse serum and 1% FBS in PBS), 
cells were stained with surface marker antibodies according to Table 4. After final washing, 
stained cells were analyzed using the multicolor flow cytometer Gallios (Beckman Coulter). 
Table 4: Fluorophore conjugated antibodies and panel specifications 
 Channels  Panel 1  Panel 2 
No. Laser (nm) 
Filter 
(nm) 
 Antibody Fluorophore Clone  Antibody Fluorophore Clone 
1 488 525/40  CD4 FITC OKT4  CD56 FITC B159 
2 488 695/30  CD3 PerCP Cy5.5 UCHT1  CD16 PerCP 3G8 
3 638 660/20  p11 APC   p11 APC  
4 638 755/LP  CD14 APC Cy7 MφP9  CD3 APC Cy7 UCHT1 
5 405 550/40  CD8 BV510 SK1  CD14 BV510 M5E2 
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3.4.4 Panel optimization 
Used lasers for excitation of fluorophores and filters for detection of fluorophore emission are 
displayed in Table 4. To minimize spectral overlap, the analysis was separated into one panel 
for T cells and one panel for NK-cells and monocytes. In channel 4, the dump channel, also 
viability stain was detected. Considerations for choosing optimal antibody-fluorophore 
combinations were separability by lasers/filters and pairing highly expressed antigens with 
dimmer fluorochromes (and vice versa). Moreover, the antibody for the protein of interest (p11) 
was conjugated towards a relatively bright fluorophore (APC). Antibody concentrations were 
titrated and separation of positive and negative cell populations was tested for by determining 
the separation index (SI)143: 






where 𝑚𝑒𝑑𝑖𝑎𝑛123 represents the median of the signal from the positive cell population, 
𝑚𝑒𝑑𝑖𝑎𝑛456 the median of the signal from the negative cell population. The denominator 
represents the right hand of the distribution of the negative cell population. The higher the SI, 
the better the separation between positive and negative cell populations. 
Even though fluorophores were chosen based on optimal separability by lasers and filters from 
each channel, emitted light by fluorophores from one channel can spill over into filters from 
another channel (Figure 10). This contribution of spill-out of each staining was determined by 
measuring the signal resulting of each stain separately, measured in the same sample. All the  
staining data used in the experiment was gathered to create a compensation matrix using 










Figure 10: Excitation (dotted lines) and emission (solid lines) spectra from three fluorophores used in 
the flow cytometry experiment: FITC (green), APC (orange) and PerCP Cy5.5 (red). Note that although 
emission spectra from APC and PerCP Cy5.5 show a large overlap, their emission spectra differ. By 
excitation of these fluorophores at different laser wavelengths (Table 4), spill-in of signal is reduced. 
Fluorophore excitation and emission data downloaded from fluorophores.org 
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3.4.5 Flow Cytometry gating strategy 
P11 levels were determined within each cell population using the following gating strategies: 
Cell populations are first gated to select single cells by excluding cells with increased forward 
scatter area vs height. Secondly, live cells gated as viability stain negative population. Then 
gating occurs based on size (forward scatter, FSC) and granularity (side scatter, SSC), in which 
lymphocytes have low FSC and SSC, while monocytes have higher SSC and high FSC.  
Furthermore, T-helper cells are gated as CD14-CD3+CD4+CD8- lymphocytes, cytotoxic T cells 
as CD14-CD3+CD4-CD8+ lymphocytes, NK cells as CD3-CD14-CD16+CD56+ lymphocytes 
and monocytes as CD3-CD14+CD56- populations. The latter is further separated into classically 
activated (CD14+CD16-) and non-classically activated (CD14+CD16+) monocytes. P11 is 
detected using APC as secondary antigen.  
Controls used for gating were the isotype control and fluorescence minus one-controls144: 
samples containing all antibody conjugates except the one which is of interest in the channel. 
Analyses were performed in FlowJo 10.4.2. Total p11 levels were calculated by multiplying 
the percentage of p11+ cells by the median fluorescence intensity of antibody staining. 
Antibody specificity towards p11 was confirmed and MFI of p11 was determined in specific 
peaks (peaks not overlapping with the isotype control).  
 
3.5 STATISTICAL ANALYSIS 
Statistical analysis was performed using R (R Development Core Team, 2020). For all 
statistical tests, the α-level was set to 0.05. 
3.5.1 Comparison of four subject groups (study I) 
To compare specific binding between the four subject groups (bipolar disorder, MDD, 
schizophrenia and healthy control), ANOVA tests were carried out together with a Tukey Post-
Hoc test to examine all pair wise comparisons and to correct for multiple comparisons.  
A paired Student’s t-test was performed to calculate differences between specific binding in 
cortical layers and Cohen’s D was calculated to determine the effect size.  
Mann-Whitney tests were used to calculate differences for comparisons of genders, where data 
showed non-normal distribution. For this data Cliff’s δ was calculated to determine the effect 
size. When analyzing differences between subject groups, p-values were adjusted for multiple 
comparisons using Bonferroni’s method.  
3.5.2 Test-retest metrics (study II) 
In study II, the following metrics were defined: 
- Coefficient of Variation (COV): shows variation between subjects and is calculated by 
dividing the SD by the mean BPND. 
- Average Absolute Percentage Difference (APD): represents an absolute value of 
normalized intra-subject differences. 
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- Intraclass Correlation Coefficient (ICC): a measure of the inter-subject differentiability. 
In this case the one-way random effects model with single measures is used (i.e. 
ICC(1,1)). ICC values range from 0-1, with 1 indicating perfect inter-subject 
differentiability. 
- Standard Error of Measurement (SEM): an estimate of precision of individual outcome 
values and is given in the unit of the measurement (here: BPND). 
- Minimal Detectable difference (MD): difference between two measurements necessary 
to be considered greater than random measurement error, according to a 95% 
confidence interval145. The MD is here given as percentage of the average BPND. 
3.5.3 Comparison between change scores in two study groups (study III-IV) 
In study III, differences in regional BPNDs, when corrected for the effect in the placebo group, 
were tested for significance by calculating the group (ketamine vs placebo) x time (pre vs post 
intervention) interaction effect in a repeated measures ANOVA (RM ANOVA).  
In study IV, non-parametric approaches were used as the requirement of normal distribution of 
MFI data was not met in all cell populations. Differences in change scores of MFI between the 
ketamine and placebo group were tested for using the two-sided Mann-Whitney U test. 
Additionally, differences in change scores between both treatment groups were also tested for 
using a linear mixed model. In this model, p11 level post-treatment was used as outcome 
measure; explained by group (ketamine vs placebo), p11 level pre-treatment and cell type as 
fixed effects; a group by cell type interaction to test the effect of treatment in each separate cell 
type and subject included as random effect (varying intercept). To reduce skewness in the data 
and stabilize variance across different cell types, the natural log of p11 values was used in the 
linear mixed model analysis. 
For exploratory analysis, differences in regional BPND (study III) and MFI (study IV) within 
the treatment group were tested using two-tailed paired Student’s t-tests and two-sided 
Wilcoxon Signed Rank Test, respectively. 
3.5.4 Correlations 
Pearson’s correlation coefficient was calculated to test for correlation of age with specific 
binding (study I) or BPND (study II).  
Correlations between MADRS scores and regional BPNDs (study III) or MFI values (study IV) 









4 RESULTS AND COMMENTS 
4.1 STUDY I 
5-HT1B receptor binding was visualized using high-resolution ARG and the radioligand 
[3H]AZ10419369 in tissue of the ACC in subjects with bipolar disorder, MDD, schizophrenia 
and healthy controls. Next to this, ARG binding was quantified and a comparison was made 
between binding distribution between patient groups, in relation to age and gender. 
A significantly higher specific binding of 5-HT1B receptor was found in the outer ACC layers 
compared to the inner ACC layers (padjusted < 0.001) (Figure 11), while no significant difference 
between patient groups was found in both cortical layers and total cortical binding. A gender 
difference was found, which was mostly profound in subjects diagnosed with MDD. As the 
tissue used in this study was distributed to several institutions, performing a wide variety of 
experiments, it was possible to perform an exploratory correlation analysis with other 
autoradiographic neuroreceptor binding distributions (8 studies available). A significant 
moderate correlation was found with glutamatergic NMDA receptor distribution ([3H]MK801 
binding), of which only binding in the outer cortical layers survived correction for multiple 







Figure 11: A) Representative tissue slice showing [3H]AZ10419369 ARG binding distribution. Middle 
and right: 35x magnification showing Nissl staining and high-resolution ARG (small dots) in outer (I) 
and inner layer (II) (scale bar = 20 μm). 
B) [3H]AZ10419369 ARG binding distribution in tissue from subjects with bipolar disorder (BD), 
major depressive disorder (MDD), schizophrenia (SZ) and healthy controls (HC). 
C) Plot with normalized specific binding values of [3H]AZ10419369 vs [3H]MK801 in outer layer. 
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No differentiation could be made in 5-HT1B receptor binding between patient groups or 
compared to controls. However, a recent PET study from our group has shown 20% lower 5-
HT1B concentrations in the ACC in MDD subjects compared to healthy controls43. The 
discrepancy compared to the in vivo results were not considered to be a lack of power in this in 
vitro ARG study, nor was the variance between subjects higher in this study. Possible reasons 
for the divergent findings could be medication use and higher severity of depression in this 
study. The latter factor would imply alterations in 5-HT1B being a state marker of depression, 
rather than a trait marker. Previously reported negative correlation between 5-HT1B receptor 
binding and age in healthy controls146 and MDD subjects43, were also not found in this study. 
This could be caused by the differences in methods for ROI delineation in ARG and PET: when 
using PET, age-affected alterations in brain volumes can be adjusted for using a PVE correcting 
algorithm, whereas in ARG gray matter volume is directly delineated. 
 
4.2 STUDY II 
The aim of this study was to improve quantification of regional [11C]AZ10419369 PET data in 
the brainstem. For this purpose, a 3D [3H]AZ10419369 ARG model was used to guide 
brainstem VOI selection for [11C]AZ10419369 PET image analysis, in which two different 
semi-automatic VOI-defining methods, based on individual136 or on template137 PET data, were 
tested and compared to a conventional method using manual delineation104.  
In vivo PET and in vitro ARG are affected by distinct factors, such as potential receptor 
degradation in post mortem tissue when using ARG and binding of endogenous compounds in 
vivo when using PET. Moreover, the different outcome values of both modalities are defined 
using different quantification methods, as discussed in the introduction. Therefore, an 
evaluation was performed on to what extent receptor distribution measured with ARG can be 
used to guide VOI definition in in vivo receptor quantification with PET. The relationship was 
tested between post mortem [3H]AZ10419369 specific binding in whole hemisphere ARG data 
of three subjects and regional BPND [11C]AZ10419369 of test-retest PET data. Binding was 
measured in nine VOIs outside the brainstem and showed a strong significant correlation 
(r=0.78, p=0.013). 
With the 3D ARG model of [3H]AZ10419369 binding, the distribution of the 5-HT1B receptor 
in brainstem tissue was visualized at high spatial resolution. This model showed continuous 
distribution of [3H]AZ10419369 binding in the dorsal midbrain and from the caudal area of the 
pons to the medulla oblongata (Figure 12A). Together with findings in literature, three 
appropriate VOIs were selected for quantification with PET: dorsal brainstem, substantia nigra 
and caudal brainstem (Figure 12B). 
Delineation of the VOIs was performed on PET data using the two semi-automatic methods. 
For delineation of the dorsal brainstem VOI, both semi-automatic methods showed 
improvements in reliability metrics compared to the conventional method (Figure 13). Both 
semi-automatic methods provided BPND values that were consistently higher and presented a 
consistently lower COV than those obtained with the conventional method. This effect was 
strongest in the individual-based method for all VOIs. Reliability for quantification in the 
dorsal and caudal brainstem VOIs was high using both semi-automatic methods. However, 
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quantification in the substantia nigra VOI resulted in moderate reliability outcomes. Future 
studies should examine other possibilities to quantify this VOI with higher reliability. 
Figure 12: A) 3D model of [3H]AZ10419369 ARG specific binding. B) Template [11C]AZ10419369 
PET data with in red the Volumes of Interest DBS (dorsal brainstem), CBS (caudal brainstem) and SN 
(substantia nigra). Both modalities are overlayed on template MRI data 
 
Figure 13: Bar plots showing reliability outcomes for each Volume of Interest (VOI) using the 
individual-based method (IBM), template-based method (TBM) and a manual method. 
APD: Absolute Percentage Difference; CBS: caudal brainstem; DBS: dorsal brainstem; ICC: Intraclass 




Although good reliability outcomes were seen for the individual-based method, an advantage 
of the template-based method is its easy implementation for future [11C]AZ10419369 PET 
data. VOIs based on individual data have to be generated for every new subject and could 
therefore be more prone to user error. 
A comparison of normalized PET template binding data in the eroded VOIs with normalized 
3D ARG signal in MNI-space showed that, throughout the brainstem, normalized BPND values 
were relatively higher than normalized specific binding values, particularly in the dorsal and 
caudal brainstem VOIs (Figure 14). These areas could be most influenced by the resolution 











Figure 14: Frequency of outcomes for log10 ratio of [11C]AZ10419369 PET BPND over 
[3H]AZ10419369 3D ARG specific binding in each voxel within the different analyzed volumes of 
interest: substantia nigra (SN), dorsal brainstem (DBS), caudal brainstem (CBS) and rest of the 
brainstem (BS). 
 
4.3 STUDY III 
In this study, the effect of a subanaesthetic dose of ketamine on 5-HT1B receptor binding using 
[11C]AZ10419369 PET was examined in SSRI-treatment resistant patients with MDD, in 
relation to treatment response. 
After the first intervention, subjects receiving ketamine showed a significant decrease in 
MADRS-scores (padjusted < 0.001; Figure 15). In the placebo group, 4 subjects believed they 
received active treatment, compared to 19 subjects in the ketamine group. MADRS-scores did 
not change significantly in the placebo group. 
No significant difference in BPND change over time between the ketamine and the placebo 
group was found in the pre-selected VOIs. Exploratory analysis within treatment groups 
showed a BPND increase of 16.7% in the hippocampus after ketamine treatment (Figure 16). 
This may reflect increased 5-HT1B receptor densities (or increased affinity of the radioligand 
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towards the receptor) or reduced serotonin concentration available to displace 
[11C]AZ10419369 binding. Therefore, this result differs from previous findings in non-human 
primates, where ketamine infusion led to increased 5-HT1B receptor binding in the ventral 
striatum (VST)76. It should be noted that there are various important difference between both 
studies: in the current study subanesthetic doses of ketamine were used instead of anesthetic 










Figure 15: Montgomery-Åsberg Depression Rating Scale (MADRS) scores after treatment with 
placebo or ketamine, followed by open-label ketamine treatment. Error bars showing SD. 
 
  
Figure 16: [11C]AZ10419369 binding in the ketamine and placebo group, before and after treatment. 
 
Baseline 5-HT1B receptor binding correlated significantly with baseline MDD symptom ratings 
(ρ=-0.426, p=0.019) and with reduction of MDD symptom ratings after ketamine treatment 
ketamine (ρ=-0.644, p=0.002). The latter correlation shows therefore an association between 
low baseline 5-HT1B receptor binding values and stronger improvements in MDD symptoms. 
The correlation of low baseline 5-HT1B receptor binding with high MADRS-scores, thus more 
severe MDD symptoms, seems in line with previous findings from Murrough et al. (2011)44, 
who showed significantly lower 5-HT1B receptor binding in MDD subjects compared to healthy 
controls, although no correlation with clinical measures was found. 
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Baseline MADRS was significantly different in both study groups. Since baseline 
[11C]AZ10419369 was shown to be correlated with baseline or changes in MADRS scores, this 
could have influenced results. However, when factoring in baseline MADRS scores in the 
analysis of BPND changes in both study groups, this did not change the results. The relatively 
high variance of MADRS changes in both treatment groups could have likely influenced the 
results, especially for the placebo group, although a placebo effect on BPND values was not 
seen. 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
4.4 STUDY IV 
Study IV was a secondary study of study III. The aim of the study was to examine the effect of 
ketamine on peripheral p11 levels in separate white blood cell populations, in relation to 
treatment response. This enabled the examination of the possibility that peripheral p11 could 
serve as a biomarker of antidepressant response of ketamine in MDD patients. P11 levels were 
determined using multicolor Flow Cytometry. 
In none of the studied cell populations, a significant difference in p11 level changes was seen 
between the ketamine and placebo group. Within treatment groups, median p11 levels were 
decreased after ketamine treatment in CD8+ cells (cytotoxic T cells; p=0.045) and CD4+ cells 
(T-helper cells; p=0.002) (Figure 17). When comparing p11 levels with treatment response, a 
significant correlation was found between baseline p11 levels in cytotoxic T cells and changes 
in MADRS scores after ketamine treatment (rho=-0.601, p=0.007). Higher baseline p11 levels 
were associated with a greater improvement in MDD symptoms. Removal of the outlier 
decreased the difference in baseline MADRS scores between both study groups, as seen in 
study III, resulting in a non-significant difference in baseline MADRS. 
 
 
Figure 17: Violin plots showing the distribution of p11 level changes after treatment with ketamine and 
placebo in cytotoxic T cells (CD8+), T-helper cells (CD4+), Classically activated monocytes (Mo-C), 
Non-classically activated monocytes (Mo-NC) and Natural Killer cells (NK). Boxes within the violin 
plot represent the interquartile range, with horizontal line representing the median and vertical lines 
representing the values within 1.5 times of the interquartile range. Outliers are shown as single dots. 
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Although not significantly different from changes seen in the placebo group, the decrease in 
p11 levels after treatment is in line with what was found in a study on the effect of the SSRI 
citalopram on p11 levels59, although no correlations were found between baseline p11 levels 
and MADRS levels or changes in the citalopram study. In the current study, a reduction of p11 
levels was found in T cells of patients in the ketamine treatment group, whereas citalopram 
was reported to mainly regulate p11 in NK cells and monocytes59. This implies a different role 
of p11 in both drugs and emphasizes cell-type regulations of p11 by therapies with distinct 







5 CONCLUSIONS AND POINTS OF PERSPECTIVES 
In this thesis, in vivo and in vitro techniques were used to study levels of the 5-HT1B receptor 
and the related protein p11 in relation to MDD and treatment with ketamine. In study I, the 
differentiability of 5-HT1B in MDD subjects compared to other psychiatric disorders and 
healthy subjects was studied using ARG. In study II, an improved method was proposed for 
quantification of 5-HT1B receptor densities in the brainstem using PET. In study III and IV, a 
potential role of cerebral 5-HT1B receptor binding and p11 levels in the antidepressant 
mechanism of action and treatment response of ketamine were studied.  
Study I: A distribution pattern of 5-HT1B receptor binding was shown in the ACC, with 
significantly higher 5-HT1B receptor binding in supragranular layers compared to infragranular 
layers. Comparison of this distribution pattern with available ARG data on the same tissue and 
in similar ROIs showed a significant correlation with the binding pattern of the NMDA 
receptor. Therefore, it is of interest to further investigate the role of 5-HT1B receptors on 
glutamate transmission in the ACC.  
5-HT1B receptor binding distributions and densities in total ACC gray matter did not 
significantly differ between subjects with bipolar disorder, schizophrenia, MDD and healthy 
controls. This finding differs from a previous PET study showing significantly lower 5-HT1B 
receptor binding in unmedicated MDD subjects compared to healthy subjects43. Therefore, it 
would be of interest to study the differences between these studies, such as the effect of chronic 
medication use on 5-HT1B receptor binding. 
In female subjects, significantly lower 5-HT1B receptor binding was found than in male 
subjects. Post-hoc analysis in the different treatment groups showed that this finding was driven 
by the MDD group. No differences in 5-HT1B binding between sexes in MDD subjects has 
been previously reported, therefore it would be of interest to investigate this further in future 
studies. 
Study II: Based on a 3D [3H]AZ10419369 ARG model from post mortem brainstem tissue and 
literature findings, three appropriate VOIs for [11C]AZ10419369 PET quantification were 
selected: a dorsal brainstem VOI, the substantia nigra and a caudal brainstem VOI. Two 
previously reported semi-automatic quantification methods, based on individual PET data136 
and based on template data137, used for quantification of 5-HTT binding data were tested. 
Comparison with a conventional manual method104 showed improved reliability for both semi-
automatic methods. Reliability outcomes were particularly high for the dorsal and caudal 
brainstem VOIs. Reliability of quantification in the substantia nigra VOI was moderate and 
should be improved using alternative methods. Although the method based on individual PET 
data showed in general highest reliability outcomes, the template-based PET method provides 
easy implementation and is less prone to user-error.  
Template VOIs based on [11C]AZ10419369 PET data of 52 healthy subjects are available for 
use in future PET studies. This study used data of healthy subjects for both creation of the 
template and testing the methods. Therefore, future studies should confirm the reliability in 




Study III: In this randomized placebo-controlled PET study, the effect of ketamine on 
[11C]AZ10419369 binding was studied in patients with SSRI-resistant MDD. 5-HT1B receptor 
binding did not significantly change in the subjects treated with ketamine compared to placebo. 
Exploratory analysis within the ketamine group showed an increase in 5-HT1B binding in the 
hippocampus after treatment. Further studies should clarify if the discrepancy with a study in 
non-human primates76 is a result of different dosages of ketamine or different timing of the 
PET examination after ketamine administration. 
Baseline 5-HT1B binding in VST correlated inversely with baseline MDD symptoms and 
reduction of depressive symptoms after ketamine treatment. Future studies should be 
conducted on the role of 5-HT1B receptors in the antidepressant mechanism of action of 
ketamine and should clarify if 5-HT1B receptor binding could be used to predict ketamine 
treatment response for SSRI-resistant MDD subjects. 
Study IV: Peripheral p11 levels were measured in the subjects from study III, before and after 
treatment with ketamine or placebo. P11 levels did not significantly change in MDD subjects 
treated with ketamine when compared to placebo. When only testing for within group changes, 
median p11 levels were shown to be decreased after ketamine treatment in both cytotoxic T 
cell and T-helper cell populations. A previous study showed a decrease of peripheral p11 levels 
in NK cells and monocytes after treatment with the SSRI citalopram59. Future studies should 
clarify if p11 could have a cell-type differentiable role in the antidepressant action of these and 
other antidepressant treatment options. 
Baseline p11 levels in cytotoxic T cells correlated significantly with changes in depressive 
symptoms, with higher baseline p11 levels being associated with greater improvements in 
MDD symptoms. This finding should be replicated in future studies to investigate if peripheral 
p11 levels in cytotoxic T cells could be used to predict treatment outcomes for ketamine 
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